These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 16200937

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
    Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
    [Abstract] [Full Text] [Related]

  • 3. [Towards a tripple oral therapy in the pharmacological treatment of type 2 diabetes?].
    Scheen AJ.
    Rev Med Liege; 2005 Aug; 60(5-6):414-8. PubMed ID: 16035303
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A, Borot S, Raccah D.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Oral antidiabetic therapy].
    Schneider S, Pazdzierny G, Klein HH.
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S264-7. PubMed ID: 17139584
    [Abstract] [Full Text] [Related]

  • 7. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M, Lam S.
    Cardiol Rev; 2007 Dec; 15(5):264-71. PubMed ID: 17700385
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Glitazones in type 2 diabetes: an update.
    Drug Ther Bull; 2008 Apr; 46(4):25-9. PubMed ID: 18403615
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration.
    Kahler KH, Rajan M, Rhoads GG, Safford MM, Demissie K, Lu SE, Pogach LM.
    Diabetes Care; 2007 Jul; 30(7):1689-93. PubMed ID: 17440170
    [Abstract] [Full Text] [Related]

  • 15. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes.
    Raskin P.
    Diabetes Metab Res Rev; 2008 Jul; 24(1):3-13. PubMed ID: 17968971
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of efficacy and safety of fixed dose combination of glimepiride 2 mg pluspioglitazone 15 mg plus metformin SR 500 mg in the management of patients with type-2 diabetes mellitus.
    Meshram DM, Langade DG, Kinagi SB, Naikwadi AA, Morye V, Chopra D.
    J Indian Med Assoc; 2005 Aug; 103(8):447-50. PubMed ID: 16363204
    [Abstract] [Full Text] [Related]

  • 17. Oral combination therapy with thiazolidinediones in type 2 diabetes.
    LaSalle JR, Cross LB.
    Am J Manag Care; 2006 Nov; 12(14 Suppl):S369-81. PubMed ID: 17112324
    [Abstract] [Full Text] [Related]

  • 18. Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria.
    Winkelmayer WC, Stedman MR, Pogantsch M, Wieninger P, Bucsics A, Asslaber M, Bauer R, Burkhardt T, Schautzer A, Brookhart MA, Pharmacoeconomics Advisory Council of the Main Association of Austrian Sickness Funds.
    Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):57-65. PubMed ID: 21182153
    [Abstract] [Full Text] [Related]

  • 19. Thiazolidinedione derivatives in type 2 diabetes mellitus.
    Tack CJ, Smits P.
    Neth J Med; 2006 Jun; 64(6):166-74. PubMed ID: 16788214
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.